Drug Trial Radar · NCT04060199
Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
Last checked: Nov 20, 2026Latest source record: Dec 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
77
Actual
Start
Apr 14, 2020
Primary completion
Oct 19, 2023
Study completion Oct 19, 2023
Sponsor
- Lead sponsor
- NS Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Nippon Shinyaku Co., Ltd.
- First posted
- Aug 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 4 years, up to 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to evaluate the efficacy of Viltolarsen compared to placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping.
Conditions
- Duchenne Muscular Dystrophy
Interventions
ViltolarsenDrug
IV infusion
PlaceboDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Time to Stand (TTSTAND) VelocityTime frame: baseline, Week 13, 25, 37, 49
Locations
40 sites in 19 countries. Site status is shown where the registry gives one.
University of California Davis Medical Center
Sacramento, California
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Queensland Children's Hospital
Brisbane, Australia
Perth Children's Hospital
Nedlands, Australia
The Childrens Hospital at Westmead
Westmead, Australia
Alberta Children's Hospital
Calgary, Canada
CHU de Quebec Research Centre
Québec, Canada
The Hospital for Sick Children (SickKids)
Toronto, Ontario, Canada
Hospital de Niños Roberto del Rio
Santiago, Chile
Pontificia Universidad Católica de Chile
Santiago, Chile
Chinese PLA General Hospital
Beijing, China
The Third Medical Center of PLA General Hospital
Beijing, China
Hunan Children's Hospital
Changsha, China
Children's Hospital of Fudan University
Shanghai, China
Shenzhen Children's Hospital
Shenzhen, China
Agia Sofia Children's Hospital
Athens, Greece
Hippokration General Hospital of Thessaloniki
Thessaloniki, Greece
Hong Kong Children's Hospital
Kowloon Bay, Hong Kong
Fondazione Policlinico Universitario A. Gemelli - Universita Cattolica del Sacro Cuore
Rome, Italy
Hospital Angeles Chihuahua
Chihuahua City, Mexico
Instituto Nacional de Pediatria
Mexico City, Mexico
Leids Universitair Medisch Centrum
Leiden, Netherlands
Radboud Universitair Medisch Centrum
Nijmegen, Gelderland, Netherlands
New Zealand Clinical Research Ltd
Auckland, New Zealand
Rikshospitalet
Oslo, Norway
Russian National Research Medical University n.a. N.I.Pirogov, structural branch - Research Clinical Institute of Pediatrics n.a. Academician Yu. E. Veltishchev
Moscow, Russia
"Saint Petersburg State Paediatric Medical University" based at Consultative and Diagnostic Centre
Saint Petersburg, Russia
Tomsk National Research Medical Center of Russian Academy of Sciences
Tomsk, Russia
Pusan National University Yangsan Hospital
Pusan, South Korea
Seoul National University Hospital
Seoul, South Korea
Hospital Sant Joan de Deu
Barcelona, Spain
Hospital Universitario La Paz
Madrid, Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Yeditepe University Kosuyolu Hospital
Istanbul, Turkey (Türkiye)
State Institution "Ukrainian Medical rehabilitation Center for Children with organic disorders of the nervous system of the Ministry of Health of Ukraine"
Kyiv, Ukraine
Birmingham Heartlands Hospital
Birmingham, United Kingdom
Royal Hospital for Children - Glasgow
Glasgow, United Kingdom
University College London Institute of Child Health
London, United Kingdom
Royal Manchester Children's Hospital
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.